Incyte Corporation · NASDAQ:INCY
Incyte — Q2 2026 Earnings Presentation
59 slides from Incyte's earnings presentation, Jul 28, 2026
Slide 1: Global Responsibility Report 2025
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Global Responsibility Report 2025 2025 Global Responsibility Report | 1
Slide 2: Table of Contents
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Table of Contents 03 06 20 23 33 42 49 Introduction Patients and Community People Environment Governance Appendix About This Report Innovation Incyte Charitable Giving Collaborative Culture Envi
Slide 3: About This Report; About Incyte
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix About This Report Our annual Global Responsibility Report details progress of our environmental, social and governance (ESG) efforts and reflects our use of rigorous science to discover, develop
Slide 4: Message from the CEO
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Message from the CEO I am pleased to share Incyte’s 2025 This work carries a responsibility—to uphold the highest standards of quality, Our Global Global Responsibility Report. Since safety and
Slide 5: 2025 Highlights
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix 2025 Highlights IMPACTING PATIENTS WORLDWIDE A RECOGNIZED LEADER Over 400,000 ~280,000 5+ global 8 patients treated with medicines commercialized by Incyte patients assisted through U.S. patient
Slide 6: Patients and Innovation
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Patients and Innovation With patients at the center of everything we do, our discovery approach focuses on building a scientifically differentiated portfolio designed to make a meaningful impact
Slide 7: Focused Portfolio
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Focused Portfolio At Incyte, we recognize the transformative power of research to drive scientific innovation and shape the future of medicine. Our portfolio is organized around three core franc
Slide 8: Clinical development pipeline
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Clinical development pipeline THERAPEUTIC AREA PROGRAM INDICATION(S) CLINICAL PROOF OF CONCEPT PIVOTAL Axatilimab 1L cGvHD (+ ruxolitinib) CSF-1R Hematology 1L cGvHD (+ steroids) CALR-mutated ET
Slide 9: Partnerships
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix PARTNERSHIPS We continuously push the boundaries of scientific discovery in treatment development, recognizing that collaboration is key to unlocking the full potential of our science. By cultiv
Slide 10: Clinical Trials
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Clinical Trials Clinical trials are essential to developing medicines that can meaningfully improve patient outcomes. 137 21 We conduct trials to evaluate treatment impacts and rely on volunteer
Slide 11: Clinical Trial Transparency, Patient Engagement and Diversity
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Clinical Trial Transparency to engage trial participants and their caregivers, pediatric and adolescent space to ensure these diversity readiness, laying the groundwork for offering tools and co
Slide 12: Protecting Patient Safety and Product Quality
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Protecting Patient Safety and Product Quality Protecting patients is at the core of what we do assessing and managing safety risks across the and requires both a strong pharmacovigilance product
Slide 13: Product Quality; Supply Chain Security and Product Integrity
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Product Quality Incyte maintains a defined management Because GxP activities we outsource directly All commercial product packs are marked with a escalation process for quality events and affect
Slide 14: Access to Medicine
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Access to Medicine We aim to ensure Incyte’s medicines are Access to Approved Medicines Increasing Global Patient Access accessible to eligible patients who need them. ~280,000 For investigation
Slide 15: Patient Education and Awareness
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Patient Education and Awareness Patient Support Resources (U.S.) Patients living with diseases in Incyte’s focus areas often face challenges accessing information and connecting with others who
Slide 16: 2025 Patient Education and Awareness Highlights
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix 2025 Patient Education and Awareness Highlights Hematology THE MPN VISUALAIZER As an extension of The Unseen Journey program, the Outside of the U.S., Incyte also convened an advisory MPN Visual
Slide 17: Oncology
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Oncology ANAL CANCER AND SQUAMOUS CELL ANAL CARCINOMA (SCAC) In 2025, Incyte launched Analcancer.com, a 10.4M people and inspired more than 423,000 highlights that while many people understand w
Slide 18: The Power of Choice with Winnie Harlow
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Inflammation & Autoimmunity (IAI) EXPANDING THE INCYTE INGENUITY AWARDS TO HIDRADENITIS SUPPURATIVA (HS) In 2025, Incyte launched the Incyte Ingenuity to $100,000. Applications will be evaluated
Slide 19: Patient Advocacy
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Patient Advocacy Incyte partners with patient advocacy organizations to address unmet patient In 2025, the U.S. MAY AUGUST needs, close education gaps and develop Oncology Eight anal cancer pati
Slide 20: Community
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Community Incyte is on a mission to Solve On and caring for others shapes how we bring that mission to life, starting with our employees and extending to the patients, caregivers and communities
Slide 21: Incyte Charitable Giving Foundation
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Incyte Charitable Giving Foundation The Incyte Charitable Giving Foundation (“the Foundation”) helps make a difference in our Delaware communities, especially in Wilmington, home to our global h
Slide 22: Community Service Program; Matching Gifts Program
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Community Service Program Giving back is part of our culture, and we encourage our employees to make a difference in their communities. Through our Community Service Program, we offer all employ
Slide 23: People
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix People At Incyte, every employee plays a role in advancing solutions that improve the lives of patients, many of whom are waiting for solutions that cannot come fast enough. That urgency shapes
Slide 24: Awards and Recognition
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Our Employees Gender Diversity Geographic Location 975 70% 940 Sales and marketing 1,456 Research and 1,364 United States development 716 Women Men and Canada General and administrative 27% 213
Slide 25: A Collaborative Culture
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix A Collaborative Culture At Incyte, innovation is not confined to a function or a role, it is a shared responsibility. From our newest hires to our Executive Leadership Team, we believe the best
Slide 26: Professional Development
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Professional Development Career growth at Incyte is collaborative, newly hired and recently promoted managers cross-functional collaboration, while also intentional, continuous and employee-driv
Slide 27: Performance Management; Internal Mobility and Career Growth
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Performance Management This supportive and collaborative approach University in Philadelphia, Pennsylvania to to performance management enhances the sponsor a two-year fellowship in Medical Incy
Slide 28: Compensation and Benefits
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Compensation and Benefits We are committed to providing competitive compensation and comprehensive benefits that enable every Incyte employee to thrive both professionally and personally. Our to
Slide 29: Enhancing Flexibility and Well-being
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Benefits Enhancing Flexibility We offer comprehensive benefits that support the needs and well-being of our global workforce. We take a data-driven approach to evaluating and enhancing our offer
Slide 30: Inclusion
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Inclusion Developing best-in-class solutions for our patients requires a collaborative, innovative and Gender (Global) 51% 33% inclusive culture. Our merit-based hiring process As of December 31
Slide 31: Safety and Wellness
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Safety and Wellness At Incyte, every employee and contractor shares international standards and best practices. Our 2022 2023 2024 2025 responsibility for reducing risk, preventing injuries inci
Slide 32: EHS Training; Emergency Preparedness; Well at Work
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix EHS Training We provide safety training as part of employee onboarding. Laboratory and manufacturing employees receive job-specific instruction covering potential hazards, including proper waste
Slide 33: Environment
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Environment As an industry leader that understands the profound connection between environmental integrity and public health, our commitment to patient well-being includes setting robust environ
Slide 34: Environmental Targets and Progress
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Environmental Targets and Progress As Incyte expands globally, we are focused Target Progress on minimizing our environmental impact and Achieve operational carbon neutrality by We continue to r
Slide 35: Environmental Oversight
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Environmental Oversight Incyte’s full Board of Directors provides oversight of our ESG strategy, including targets and initiatives designed to reduce our environmental impact. Specific Board Com
Slide 36: Emissions Reduction
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Emissions Reduction 12 Since establishing our 2019 baseline, we’ve taken meaningful steps to reduce absolute Scope 1 and 2 emissions, even as our square footage, employee headcount and revenue 2
Slide 37: Scope 1 and Scope 2 Emissions
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Scope 1 and Scope 2 Emissions13 Metric 2019 2023 2024 2025 Scope 1 emissions (MTCO2e) 4,775 9,351 9,576 8,872 Scope 2 emissions (Location-based) (MTCO2e) 7,450 6,079 6,516 6,709 Total Scope 1 &
Slide 38: Energy Reduction at our Facilities
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Energy Reduction at our Facilities Energy Consumption – Buildings Only14 As of April 2026, our owned facilities account for approximately 70% of our total square footage. While these sites repre
Slide 39: Emissions Offsets; Scope 3 Emissions; Green Initiatives
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Emissions Offsets 15 SCOPE 3 EMISSIONS CATEGORIES 16 Reducing our carbon footprint is our primary focus, with carbon credits serving as a complementary Metric 2019 2023 2024 2025 tool to achieve
Slide 40: Water Conservation
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Water Conservation Across our global footprint, we strive to conserve We comply with local regulations for wastewater water. All new and renovated spaces are permitting and handling, submitting
Slide 41: Waste Management
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Waste Management Incyte is committed to reducing waste and fuel-blended or otherwise disposed of at a facility Waste Metrics (Metric Tons)24, 25 managing it responsibly in accordance with all ov
Slide 42: Governance and Risk Management
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Governance and Risk Management Strong ethics and good governance are fundamental to creating both long-term value for our shareholders and broad positive impacts for our patients, employees, com
Slide 43: Corporate Governance
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Corporate Governance We believe engaged directors with diverse backgrounds are critical for effective oversight. ESG Oversight Our Board members bring a wealth of scientific knowledge, extensive
Slide 44: Responsible Research and Development
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Responsible Research and Development At Incyte, we take seriously our responsibility to patients, employees, shareholders and the biomedical research community. Maintaining high ethical standard
Slide 45: Ethics and Compliance Program
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Ethics and Compliance Program Incyte implements a comprehensive Compliance Program that helps us maintain easily accessible written standards, provide ongoing education and training, conduct ris
Slide 46: Ethics and Compliance Training; LC eGuide Launch
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Ethics and Compliance Training and Resources LC eGuide Launch We clearly communicate our ethical standards During Corporate Compliance & Ethics Week in 2025, we reinforced our commitment to inte
Slide 47: Ethical Marketing; Human Rights
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Ethical Marketing Human Rights To ensure practitioners and patients can guidelines. Employees in promotional roles receive At the core of Incyte’s purpose to find solutions and the International
Slide 48: Cybersecurity and Data Privacy; Our Approach to Tax
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Cybersecurity and Data Privacy Our Approach to Tax We honor the relationships we’ve built with partners. Incyte has not been required to report a As a biopharmaceutical company, we have Responsi
Slide 49: Appendix
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Appendix 2025 Global Responsibility Report | 49
Slide 50: UN SDGs; TCFD
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix UN SDGs on our business strategy and financial planning information technology risks. Within these risks, that may become more frequent due to climate for the future. Each year, we strive to enh
Slide 51: TCFD Strategy
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix STRATEGY At Incyte, we have a well-defined strategy Following our initial climate risk evaluation, we focused on addressing critical unmet medical performed an updated climate risk assessment ne
Slide 52: Transition Risks
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Transition Risks RISK TYPE CLIMATE-RELATED RISK TIME HORIZON (S, M, L) RISK IMPACT MITIGATION Policy and Legal Enhanced reporting obligations due to climate S, M Expenditures - Increased operati
Slide 53: Transition Risks (Market)
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Transition Risks RISK TYPE CLIMATE-RELATED RISK TIME HORIZON (S, M, L) RISK IMPACT MITIGATION Market Increased cost and disruption to raw materials S, M, L Expenditures - Increased operating exp
Slide 54: Physical Risks
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Physical Risks RISK TYPE CLIMATE-RELATED RISK TIME HORIZON (S, M, L) RISK IMPACT MITIGATION Acute Increased severity and frequency of flooding M, L Expenditures – Increased direct and indirect c
Slide 55: Climate-related Opportunities
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Climate-related Opportunities OPPORTUNITY TYPE CLIMATE-RELATED OPPORTUNITY TIME HORIZON (S, M, L) OPPORTUNITY IMPACT MANAGEMENT Energy resource Use of lower-emission sources of energy S, M, L Ex
Slide 56: Climate Resilience: Impact on Strategy & Financial Planning
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix Climate Resilience: Impact on Strategy also make clinical trial sites inaccessible or delay Low-Warming Future (<2°C) global healthcare innovation and help sustain & Financial Planning patient v
Slide 57: Risk Management
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix RISK MANAGEMENT potential impacts at each of our locations under gas emissions, energy use, water consumption Our risk assessment processes allow us to a carbon-intensive scenario (aligned with
Slide 58: SASB
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix SASB Accounting Metric Code Disclosure Accounting Metric Code Disclosure Safety of Clinical Trial Participants Counterfeit Drugs Discussion, by world region, of management process for ensuring q
Slide 59: Introduction Patients and Innovation Community
Introduction Patients and Innovation Community People Environment Governance and Risk Management Appendix © 2012-2026 Incyte 2025 Global Responsibility Report | 59